Pharming Group (NASDAQ:PHAR) Earns Buy Rating from Analysts at Jefferies Financial Group

Jefferies Financial Group initiated coverage on shares of Pharming Group (NASDAQ:PHAR) in a research note issued to investors on Monday, Marketbeat Ratings reports. The brokerage issued a buy rating and a $14.00 price objective on the stock.

A number of other equities analysts have also issued reports on PHAR. Oppenheimer dropped their target price on shares of Pharming Group from $31.00 to $30.00 and set an “outperform” rating on the stock in a research report on Monday, October 28th. HC Wainwright reaffirmed a “buy” rating and set a $37.00 target price on shares of Pharming Group in a research report on Thursday, October 24th.

Pharming Group Trading Up 6.1 %

Shares of PHAR stock opened at $9.27 on Monday. Pharming Group has a 1 year low of $6.65 and a 1 year high of $13.20. The firm’s fifty day simple moving average is $8.23 and its 200 day simple moving average is $8.14. The firm has a market capitalization of $628.83 million, a P/E ratio of -35.65 and a beta of 0.05. The company has a current ratio of 3.53, a quick ratio of 2.76 and a debt-to-equity ratio of 0.41.

Institutional Investors Weigh In On Pharming Group

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC boosted its holdings in shares of Pharming Group (NASDAQ:PHAR) by 75.4% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 41,110 shares of the company’s stock after buying an additional 17,675 shares during the period. Silverberg Bernstein Capital Management LLC owned about 0.06% of Pharming Group worth $339,000 as of its most recent SEC filing. 0.03% of the stock is owned by institutional investors.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.